Many commercial DBMs utilize an inert carrier to improve handling, and the proportion of demineralized bone content in the graft varies widely by manufacturer. These carriers do not have a biological function, and they can dilute the osteoinductive potential of the graft.1In addition, carriers can negatively affect the release of growth factors2and functionality of native cells.3 PliaFX contains 100% bone and provides optimized handling without compromising the osteoconductive and osteoinductive properties necessary for bone formation.
100% Bone: Grows more bone than DBMs containing a carrier, as demonstrated in literature.4
Optimized Handling: Interlocking cortical fibers become moldable upon rehydration and resist migration without the use of a carrier.5
Versatility: Easily mixes with autograft, allograft, and/or fluid of surgeon’s choice.6
1. Han B, Tang B, Nimni ME. Quantitative and sensitive in vitro assay for osteoinductive activity of demineralized bone matrix. J Orthop Res. 2003;21(4):648-654.
2. Lee JH, Baek H-R, Lee KM, et al. The Effect of Poloxamer 407-Based Hydrogel on the Osteoinductivity of Demineralized Bone Matrix. Clinics in Orthopedic Surgery. 2014;6(4):455-461.
3. Murphy MB, Suzuki RK, Sand TT, Chaput CD, Gregory CA. Short Term Culture of Human Mesenchymal Stem Cells with Commercial Osteoconductive Carriers Provides Unique Insights into Biocompatibility. J Clin Med. 2013;2(3):49-66.
4. Boyan BD, Ranly DM, McMillan J, et al. Osteoinductive Ability of Human Allograft Formulations. J. Periodontol. September 2003.
5. Data on file. LifeNet Health ES-17-090
6. Data on file. LifeNet Health ES-16-085